OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression." Tong and a team of researchers have reported that oral squamous cell carcinoma (OSCC) cells endogenously produce exceptionally high levels of vascular endothelial growth factor (VEGF). In addition to its proangiogenic function, they observed that VEGF fulfills an autocrine-paracrine role in OSCC by directly promoting OSCC cell proliferation and invasion.

Despite their epithelial origin, cultured OSCC cells express both VEGFR1 and VEGFR2 and serve as both targets and effectors for VEGF. Furthermore, the recognized angiostatic agent, Endostatin, inhibits OSCC cell migration and invasion. Therefore, the researchers of this study hypothesize that at least a subpopulation of OSCC cells have the capability to undergo an "epithelial-to-endotheliod transition" and this process facilitates OSCC progression.

The results of the study imply that OSCC cells undergo a phenotypic transition that endows endotheliod characteristics which augment VEGF production (with associated autocrine-paracrine functions) and facilitate OSCC cell mobility, enabling angiogenesis, tumor progression and metastases. These OSCC-endothelial cell commonalities introduce the prospect for concurrent antiangiogenic/antitumorigenic therapies.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Axxam and B'SYS partner to expand access to validated ion channel cell lines for high-throughput electrophysiology